SCHEMBL6168486

SCHEMBL6168486

Cc1ccc(C(=O)Cc2ccc(S(N)(=O)=O)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 10/20 0.62
CA2 P00918 10/20 0.62
CA9 Q16790 8/20 0.62
CA12 O43570 8/20 0.62
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
CA7 P43166 3/20 0.58
CA3 P07451 1/20 0.58
CA6 P23280 1/20 0.58
CA5A P35218 1/20 0.58
CA5B Q9Y2D0 1/20 0.58
PTPN7 P35236 1/20 0.55
CA4 P22748 1/20 0.53
MEN1 O00255 1/20 0.50
POLB P06746 1/20 0.50
KMT2A Q03164 1/20 0.50
KDM4E B2RXH2 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
ALDH1A1 P00352 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL780498 0.85 NPC1 (0.63) CA1CA2CA9CA12NPC1
SCHEMBL6180942 0.85 NPC1 (0.63) NPC1RAB9AL3MBTL1KMT2A
SCHEMBL5218244 0.84 NPC1 (0.81) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL6024972 0.84 CA2 (0.62) CA1CA2CA9CA12CA7
SCHEMBL6026667 0.83 CA1 (0.61) CA1CA2CA9CA12CA7
SCHEMBL6168504 0.83 CA2 (0.65) CA1CA2CA9CA12NPC1
SCHEMBL20017608 0.80 NPC1 (0.69) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL7866978 0.78 KMT2A (0.60) NPC1RAB9AL3MBTL1KMT2AKDM4E
SCHEMBL12637601 0.78 NPC1 (0.71) CA2NPC1RAB9AL3MBTL1MEN1
SCHEMBL28629860 0.78 NPC1 (0.71) CA2NPC1RAB9AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1528059-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle LLC (US) 2005-05-04 EP disclosed
US-6670365-B1 Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2003-12-30 US disclosed
EP-1104762-B1 SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 S A L V A T LAB SA (ES) 2002-09-18 EP disclosed
EP-0809636-B1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-04 EP disclosed
EP-1223167-A2 Substituted isoxazoles for the treatment of inflammation G.D. Searle & Co. (US) 2002-07-17 EP disclosed
EP-1104762-A1 SUBSTITUTED IMIDAZO 1,2A]AZINES AS SELECTIVE INHIBOTORS OF COX-2 LABORATORIOS S.A.L.V.A.T., S.A. (ES) 2001-06-06 EP disclosed
US-5859257-A ANTIINFLAMMATORY, ANTIARTHRITIC AGENTS G. D. SEARLE & CO. (US) 1999-01-12 US disclosed
EP-0809636-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-12-03 EP disclosed
WO-1996025405-A1 SUBSTITUTED ISOXAZOLES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-08-22 WO disclosed